For patients with prostate cancer, concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs does not increase risks for thrombosis or bleeding.
Study finds similar safety regardless of anticoagulant type.In a study of adults with advanced prostate cancer taking androgen-receptor pathway ...
Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of side effects, a study suggests. Using AI, scientists found that images ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results